The Pfizer Vaccines US Medical Affairs Team will be offering an educational webinar series titled Translating mRNA which is focused on providing education on COVID-19 and vaccination. The webinar series is designed to communicate scientific information including recent study results to support healthcare providers’ knowledge regarding Pfizer and BioNTech’s COVID-19 Vaccines including the COVID-19 vaccine, Bivalent (Original and Omicron BA.4/BA.5).

The webinar series will include a live question-and-answer session with Pfizer medical experts.

The following Translating mRNA sessions on the topics below will be hosted:

1. Select Bivalent COVID-19 Vaccine Information Presented at Recent FDA Advisory Committee Meeting
Monday, 13 February 2023: 12:00 pm – 1:00 pm EST or
Tuesday, 14 February 2023: 5:00 pm – 6:00 pm EST or
Wednesday, 15 February 2023: 3:00 pm – 4:00 pm EST

Speaker: Rajeev M Nepal, PhD
Medical Director, Pfizer mRNA Vaccines, Medical and Scientific Affairs, USA

2. COVID-19 Vaccination: Considerations for Pediatric Patients
Monday, 27 February 2023: 12:00 pm – 1:00 pm EST or
Tuesday, 28 February 2023: 5:00 pm – 6:00 pm EST or
Wednesday, 01 March 2023: 3:00 pm – 4:00 pm EST

Speaker: Maria D. McColgan, MD, MSEd
Medical Director, Pfizer mRNA Vaccines, Medical and Scientific Affairs, USA

Target Audience: All healthcare professionals including but not limited to physicians, nurse practitioners, pharmacists, and physician assistants.

*Continuing medical education credit is NOT associated with this event. *

For more information, please see the full Prescribing Information and EUA Fact Sheets for Vaccination Providers here.

Emergency uses of the vaccines have not been approved or licensed by the US Food and Drug Administration (FDA) but have been authorized by the FDA under an Emergency Use Authorization (EUA) to prevent COVID-19 in individuals aged 6 months and older for the Pfizer-BioNTech COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine, Bivalent. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.